Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Monte Rosa Therapeutics, Inc. seeks a Senior Manager, FP&A to drive planning, forecasting and analytics across a substantial portion of operating expenses.
You will partner with department leaders to translate strategic priorities into credible financial plans and board-ready materials. You will own the annual plan, quarterly reforecasts, monthly close, cash/runway analysis and long-range scenarios, while collaborating with both scientific and corporate teams to optimize resource allocation and
We are seeking a Senior Manager, FP&A to join our Boston-based Finance team. Reporting to the Director, FP&A, this individual will support and own planning, forecasting, and analytics across a significant portion of the Company's operating expense base, partnering directly with department leaders to translate strategic priorities into credible financial plans.
This is a broad, high-visibility role with exposure to both our scientific organization and our corporate functions. You will be a core contributor to the annual planning cycle, quarterly reforecasts, monthly close, cash and runway analysis, and Board-level reporting. The scope is intentionally wide — we are looking for someone who wants to understand how the whole company works, not just one slice of it.
Monte Rosa Therapeutics (MRT) is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.